329 related articles for article (PubMed ID: 26153518)
1. Evaluation of cholesterol metabolism in cerebrotendinous xanthomatosis.
Mignarri A; Magni A; Del Puppo M; Gallus GN; Björkhem I; Federico A; Dotti MT
J Inherit Metab Dis; 2016 Jan; 39(1):75-83. PubMed ID: 26153518
[TBL] [Abstract][Full Text] [Related]
2. Isotopomer spectral analysis of intermediates of cholesterol synthesis in patients with cerebrotendinous xanthomatosis.
Clarenbach JJ; Lindenthal B; Dotti MT; Federico A; Kelleher JK; von Bergmann K
Metabolism; 2005 Mar; 54(3):335-44. PubMed ID: 15736111
[TBL] [Abstract][Full Text] [Related]
3. Transformation of 4-cholesten-3-one and 7 alpha-hydroxy-4-cholesten-3-one into cholestanol and bile acids in cerebrotendinous xanthomatosis.
Salen G; Shefer S; Tint GS
Gastroenterology; 1984 Aug; 87(2):276-83. PubMed ID: 6735073
[TBL] [Abstract][Full Text] [Related]
4. The safety and effectiveness of chenodeoxycholic acid treatment in patients with cerebrotendinous xanthomatosis: two retrospective cohort studies.
Verrips A; Dotti MT; Mignarri A; Stelten BML; Verma S; Federico A
Neurol Sci; 2020 Apr; 41(4):943-949. PubMed ID: 31863326
[TBL] [Abstract][Full Text] [Related]
5. On the substrate specificity of human CYP27A1: implications for bile acid and cholestanol formation.
Norlin M; von Bahr S; Bjorkhem I; Wikvall K
J Lipid Res; 2003 Aug; 44(8):1515-22. PubMed ID: 12777473
[TBL] [Abstract][Full Text] [Related]
6. Cerebrotendinous xanthomatosis: an inborn error in bile acid synthesis with defined mutations but still a challenge.
Björkhem I; Hansson M
Biochem Biophys Res Commun; 2010 May; 396(1):46-9. PubMed ID: 20494109
[TBL] [Abstract][Full Text] [Related]
7. Metabolic profiling in serum, cerebrospinal fluid, and brain of patients with cerebrotendinous xanthomatosis.
Höflinger P; Hauser S; Yutuc E; Hengel H; Griffiths L; Radelfahr F; Howell OW; Wang Y; Connor SL; Duell PB; DeBarber AE; Martus P; Lütjohann D; Griffiths WJ; Schöls L
J Lipid Res; 2021; 62():100078. PubMed ID: 33891937
[TBL] [Abstract][Full Text] [Related]
8. Cerebrotendinous xanthomatosis.
Björkhem I
Curr Opin Lipidol; 2013 Aug; 24(4):283-7. PubMed ID: 23759795
[TBL] [Abstract][Full Text] [Related]
9. Genetically and clinically confirmed atypical cerebrotendinous xanthomatosis with normal cholestanol and marked elevations of bile acid precursors and bile alcohols.
DeBarber AE; Schaefer EJ; Do J; Ray JW; Larson A; Redder S; Fowler M; Duell PB
J Clin Lipidol; 2024; 18(3):e465-e476. PubMed ID: 38637260
[TBL] [Abstract][Full Text] [Related]
10. High levels of plant sterols and cholesterol precursors in cerebrotendinous xanthomatosis.
Kuriyama M; Fujiyama J; Kasama T; Osame M
J Lipid Res; 1991 Feb; 32(2):223-9. PubMed ID: 2066659
[TBL] [Abstract][Full Text] [Related]
11. Chenodeoxycholic Acid: An Update on Its Therapeutic Applications.
Fiorucci S; Distrutti E
Handb Exp Pharmacol; 2019; 256():265-282. PubMed ID: 31267167
[TBL] [Abstract][Full Text] [Related]
12. [Laboratory diagnosis of a rare congenital neurodegenerative disease: cerebrotendinous xanthomatosis].
Varga VE; Katkó M; Harangi J; Balogh I; Kapás I; Madar L; Seres I; Molnár MJ; Paragh G; Kovács GG; Harangi M
Orv Hetil; 2014 May; 155(21):811-6. PubMed ID: 24836315
[TBL] [Abstract][Full Text] [Related]
13. Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis.
Verrips A; Wevers RA; Van Engelen BG; Keyser A; Wolthers BG; Barkhof F; Stalenhoef A; De Graaf R; Janssen-Zijlstra F; Van Spreeken A; Gabreëls FJ
Metabolism; 1999 Feb; 48(2):233-8. PubMed ID: 10024088
[TBL] [Abstract][Full Text] [Related]
14. Differences in hepatic levels of intermediates in bile acid biosynthesis between Cyp27(-/-) mice and CTX.
Honda A; Salen G; Matsuzaki Y; Batta AK; Xu G; Leitersdorf E; Tint GS; Erickson SK; Tanaka N; Shefer S
J Lipid Res; 2001 Feb; 42(2):291-300. PubMed ID: 11181760
[TBL] [Abstract][Full Text] [Related]
15. Treatment of cerebrotendinous xanthomatosis: effects of chenodeoxycholic acid, pravastatin, and combined use.
Kuriyama M; Tokimura Y; Fujiyama J; Utatsu Y; Osame M
J Neurol Sci; 1994 Aug; 125(1):22-8. PubMed ID: 7964884
[TBL] [Abstract][Full Text] [Related]
16. Treatment with chenodeoxycholic acid in cerebrotendinous xanthomatosis: clinical, neurophysiological, and quantitative brain structural outcomes.
Amador MDM; Masingue M; Debs R; Lamari F; Perlbarg V; Roze E; Degos B; Mochel F
J Inherit Metab Dis; 2018 Sep; 41(5):799-807. PubMed ID: 29560583
[TBL] [Abstract][Full Text] [Related]
17. Age-related changes of cholestanol and lathosterol plasma concentrations: an explorative study.
Gelzo M; Di Taranto MD; Sica C; Boscia A; Papagni F; Fortunato G; Corso G; Dello Russo A
Lipids Health Dis; 2019 Dec; 18(1):235. PubMed ID: 31888647
[TBL] [Abstract][Full Text] [Related]
18. Long-term bone density evaluation in cerebrotendinous xanthomatosis: evidence of improvement after chenodeoxycholic acid treatment.
Martini G; Mignarri A; Ruvio M; Valenti R; Franci B; Del Puppo M; Federico A; Nuti R; Dotti MT
Calcif Tissue Int; 2013 Mar; 92(3):282-6. PubMed ID: 23212544
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX).
Salen G; Steiner RD
J Inherit Metab Dis; 2017 Nov; 40(6):771-781. PubMed ID: 28980151
[TBL] [Abstract][Full Text] [Related]
20. Could steroids mask the diagnosis of cerebrotendinous xanthomatosis?
Siman-Tov T; Meiner V; Gadoth N
J Neurol Sci; 2006 Apr; 243(1-2):83-6. PubMed ID: 16445943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
